Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedJan 29, 2026
DataAggregated Company Financials
Companies151
  • 7D1.9%
  • 3M-5.9%
  • 1Y-8.0%
  • YTD-0.3%

The Healthcare industry is up 2.5% in the last week, with BioArctic up 11%. During this same period, the Getinge underperformed, falling 5.7%. However, the industry is down 6.5% over the past year. As for the next few years, earnings are expected to grow by 26% per annum.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 29 Jan 2026SEK 597.5bSEK 256.6bSEK 5.1b39.1x118x2.3x
Sat, 27 Dec 2025SEK 583.9bSEK 230.5bSEK 3.6b43.6x160.1x2.5x
Mon, 24 Nov 2025SEK 583.3bSEK 230.8bSEK 3.3b44.3x179.4x2.5x
Wed, 22 Oct 2025SEK 600.5bSEK 227.8bSEK 2.3b43.2x257.5x2.6x
Fri, 19 Sep 2025SEK 613.1bSEK 227.3bSEK 6.6b46.4x92.9x2.7x
Sun, 17 Aug 2025SEK 609.0bSEK 226.8bSEK 6.6b46.3x92x2.7x
Tue, 15 Jul 2025SEK 638.8bSEK 226.7bSEK 6.0b44.9x106x2.8x
Thu, 12 Jun 2025SEK 623.7bSEK 226.5bSEK 5.8b41.9x107.3x2.8x
Sat, 10 May 2025SEK 600.8bSEK 224.1bSEK 5.2b34.5x114.9x2.7x
Mon, 07 Apr 2025SEK 537.6bSEK 221.5bSEK 5.4b32.5x99.5x2.4x
Wed, 05 Mar 2025SEK 570.8bSEK 206.4bSEK 4.7b35.3x122.4x2.8x
Fri, 31 Jan 2025SEK 600.0bSEK 203.9b-SEK 2,764,331,751.2442.4x-217x2.9x
Sun, 29 Dec 2024SEK 584.7bSEK 202.6b-SEK 2,502,972,536.0639x-233.6x2.9x
Tue, 26 Nov 2024SEK 514.7bSEK 199.9b-SEK 2,629,893,848.3137.3x-195.7x2.6x
Thu, 24 Oct 2024SEK 588.3bSEK 199.2b-SEK 3,256,284,366.3241.6x-180.7x3x
Sat, 21 Sep 2024SEK 615.2bSEK 200.1b-SEK 2,816,505,402.9141.3x-218.4x3.1x
Mon, 19 Aug 2024SEK 599.4bSEK 200.3b-SEK 2,676,027,021.8440.9x-224x3x
Wed, 17 Jul 2024SEK 583.2bSEK 196.5b-SEK 3,061,535,018.1141.6x-190.5x3x
Fri, 14 Jun 2024SEK 566.4bSEK 195.5b-SEK 3,141,492,352.5735.7x-180.3x2.9x
Sun, 12 May 2024SEK 549.1bSEK 196.7b-SEK 2,684,395,063.5536.5x-204.6x2.8x
Tue, 09 Apr 2024SEK 530.1bSEK 192.6b-SEK 3,172,797,660.6145.3x-167.1x2.8x
Thu, 07 Mar 2024SEK 512.8bSEK 192.1b-SEK 3,657,426,288.5044.3x-140.2x2.7x
Sat, 03 Feb 2024SEK 537.5bSEK 193.6b-SEK 4,970,986,818.0050.1x-108.1x2.8x
Mon, 01 Jan 2024SEK 541.1bSEK 191.2b-SEK 963,424,829.0048.2x-561.6x2.8x
Wed, 29 Nov 2023SEK 498.1bSEK 189.9b-SEK 1,210,055,600.0050.5x-411.6x2.6x
Fri, 27 Oct 2023SEK 427.3bSEK 187.0b-SEK 1,842,456,833.0029.3x-231.9x2.3x
Sun, 24 Sep 2023SEK 456.9bSEK 185.6b-SEK 2,045,479,582.0036.3x-223.4x2.5x
Tue, 22 Aug 2023SEK 457.5bSEK 185.0b-SEK 1,103,255,988.0039.6x-414.7x2.5x
Thu, 20 Jul 2023SEK 473.4bSEK 181.8b-SEK 1,728,561,475.0043.7x-273.9x2.6x
Sat, 17 Jun 2023SEK 521.9bSEK 179.0b-SEK 773,290,123.0045x-675x2.9x
Mon, 15 May 2023SEK 518.1bSEK 176.8b-SEK 880,321,524.0042.2x-588.5x2.9x
Wed, 12 Apr 2023SEK 510.8bSEK 172.7b-SEK 1,425,112,828.0035.9x-358.4x3x
Fri, 10 Mar 2023SEK 490.9bSEK 172.5b-SEK 1,625,503,281.0037.1x-302x2.8x
Sun, 05 Feb 2023SEK 529.8bSEK 167.4bSEK 208.6m35.8x2540x3.2x
Price to Earnings Ratio

2540x


Total Market Cap: SEK 529.8bTotal Earnings: SEK 208.6mTotal Revenue: SEK 167.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -147.5x202420252026
Current Industry PE
  • Investors are optimistic on the Swedish Healthcare industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 124x which is higher than its 3-year average PE of -148x.
  • The 3-year average PS ratio of 2.7x is higher than the industry's current PS ratio of 2.3x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 185% per year over the last three years.
  • Revenues for these companies have grown 15% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market1.03%
Healthcare1.85%
Biotech4.19%
Pharma2.83%
Healthcare Services1.88%
Healthtech1.49%
Medical Equipment-1.24%
Life Sciences-2.15%
Industry PE
  • Investors are most optimistic about the Biotech industry which is trading above its 3-year average PE ratio.
    • Analysts are expecting annual earnings growth of 29.4%, which is higher than its past year's earnings decline of 6.2% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 38% over the next 5 years.
  • However this is lower than its past earnings growth rate of 97% per year.
  • In contrast, the Healthtech industry is expected to see its earnings grow by 18% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
BIOA B BioArcticSEK 322.804.0%
+SEK 1.8b		41.5%PE47.9x
SOBI Swedish Orphan BiovitrumSEK 336.200.9%
+SEK 1.0b		-1.1%PE8913.3x
IMP A SDB ImplanticaSEK 49.402.9%
+SEK 396.6m		23.5%PS667.2x
XVIVO Xvivo PerfusionSEK 236.205.4%
+SEK 384.3m		-49.7%PE295.7x
DMYD B Diamyd MedicalSEK 15.7819.0%
+SEK 346.5m		-8.1%PS6217x

Latest News

ALIF B
SEK 138.80
AddLife
7D
-6.3%
1Y
-6.8%
DMYD B
SEK 15.78
Diamyd Medical
7D
19.0%
1Y
-8.1%
GETI B
SEK 196.35
Getinge
7D
-7.0%
1Y
-10.3%

GETI B: Higher Dividend Proposal Will Underpin Future Shareholder Returns

Analysts have trimmed their fair value estimate for Getinge to SEK229 from SEK236, reflecting updated assumptions around discount rates, revenue growth, profit margins and future price-to-earnings (P/E) expectations. What's in the News Getinge AB (publ) announced a proposed dividend per share of SEK 4.75 compared with SEK 4.60 in the prior period, indicating an updated payout proposal for shareholders (Key Developments).
XVIVO
SEK 236.20
Xvivo Perfusion
7D
5.4%
1Y
-49.7%
VITR
SEK 118.40
Vitrolife
7D
-6.4%
1Y
-49.6%

VITR: Restructuring And Goodwill Impairment Will Drive Future Upside Potential

Analysts have trimmed their price target on Vitrolife from SEK188.75 to SEK187.00, reflecting adjustments to revenue growth and discount rate assumptions, along with updated views on profit margin and future P/E levels. What's in the News Vitrolife plans a restructuring program for its genetic services business, targeting annualised savings of SEK 65 million.
ATT
SEK 89.70
Attendo
7D
2.5%
1Y
71.8%

ATT: Stable Margins And Tweaked Assumptions Will Support Measured Future Returns

Analysts have slightly adjusted their price target on Attendo, with the updated fair value now cited at €90.0. This reflects modest tweaks to assumptions for discount rate, revenue growth, profit margin, and future P/E, rather than a major shift in their view of the company. Valuation Changes Fair Value: Held steady at €90.0, indicating no change in the overall assessed equity value.
SANION
SEK 27.00
Saniona
7D
9.3%
1Y
243.5%
BIOA B
SEK 322.80
BioArctic
7D
4.0%
1Y
41.5%

BIOA B: Future Earnings Will Rely On Risky China Alzheimer Access

Analysts now keep their price target for BioArctic at SEK 230.00, with small adjustments to the discount rate, revenue growth assumptions and future P/E outlook. This reflects only minor changes to their overall view of the company’s risk and profitability profile.
VIMIAN
SEK 27.26
Vimian Group
7D
-5.2%
1Y
-32.4%
EKTA B
SEK 58.95
Elekta
7D
-3.4%
1Y
-11.1%
SOBI
SEK 336.20
Swedish Orphan Biovitrum
7D
0.9%
1Y
-1.1%

SOBI: Upgraded Buy Rating And Pipeline Progress Are Expected To Drive Returns

Analysts have nudged their price target for Swedish Orphan Biovitrum slightly higher to SEK 372.42 from SEK 371.18. This reflects updated assumptions on discount rate, revenue growth, profit margin and future P/E after recent research including an upgrade to Buy.
BONEX
SEK 186.90
Bonesupport Holding
7D
-7.0%
1Y
-45.6%

BONEX: De Novo Review Shift Will Support Long Term Upside Potential

Analysts have trimmed their price target for Bonesupport Holding to SEK 374.60 from SEK 391.20, citing slightly lower assumptions for revenue growth and profit margins, along with a higher future P/E multiple. What's in the News Bonesupport Holding issued earnings guidance for the fourth quarter of 2025 with net sales expected at SEK 313 M, based on constant exchange rates (Corporate guidance).
IMP A SDB
SEK 49.40
Implantica
7D
2.9%
1Y
23.5%
CAMX
SEK 670.50
Camurus
7D
-2.8%
1Y
12.3%

CAMX: Guidance Cut Will Be Offset By Pipeline Progress And New Partnership

Analysts have kept their price target for Camurus steady at SEK 660, citing updated assumptions around revenue growth, a profit margin of 72.87% and a future P/E of 12.70 as key inputs to their valuation work. What's in the News The U.S. FDA accepted Camurus' resubmitted New Drug Application for Oclaiz (CAM2029) for acromegaly, with a PDUFA target action date of 10 June 2026.
ASKER
SEK 75.80
Asker Healthcare Group
7D
-4.7%
1Y
n/a
EGTX
SEK 5.22
Egetis Therapeutics
7D
11.9%
1Y
-13.7%